Metin GÜÇLÜ, Berkant KADERLİ, Canan ERSOY

Comparison of Conventional Inflammatory Parameters with Tumor Necrosis Factor-α Levels in Different Stages of Diabetic Retinopathy and Non-Diabetic Controls

Aim of this study was to identify the risk factors associated with diabetic retinopathy in patients with Type 2 diabetes mellitus(DM), and to compare the levels of erythrocyte sedimentation rate (ESR), high sensitive CRP(hs-CRP) and tumor necrosis factor-α (TNF-α), in patients with every stage of diabetic retinopathy and non-diabetic healthy controls. A total of 79 individuals, 64 diabetic and 25 healthy controls were included in the study. Patients were divided into three groups. Group 1 consisted of those without diabetic retinopathy (DR) (n=26), group 2 with non-proliferative (NPDR) (n=19), and group 3 with proliferative diabetic retinopathy (PDR) (n=19). Even though the similar age distribution, disease duration were different as 6.9 ± 6.5, 10.3 ± 5.4, and 12.7 ± 5.1 years in Group 1, Group 2 and Group 3, respectively (p>0.001). The majority of the patients with PDR were male, had high levels of albuminuria and high percents of receiving insulin treatment (p

PDF

___

1. Cumbie BC, Hermayer KL. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag. 2007;3(6):823-32.

2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401-11.

3. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-53.

4. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902-16.

5. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136(1):122- 35.

6. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16:242-60.

7. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;16(3):242-60.

8. Szalai AJ. The biological functions of C-reactive protein Vascul Pharmacol. 2002;39(3):105-7.

9. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2-3):189-97.

10. Llorca J, González Quirós M, Sampedro I, García Unzueta MT, Berrazueta JR. Reproducibility of C-reactive protein analyses. Rev Esp Cardiol. 2002;55(10):1101-4.

11. Niessen HW, Hack CE. C-reactive protein and the risk of cardiovascular mortality. Am J Med. 2003;(3):241-2.

12. Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med. 2003;114(3):199-205.

13. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61 Suppl 1:S9-S18.

14. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 2000;46(4):461-8.

15. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-7.

16. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155(1):57-64.

17. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 2003;14(5):447-55.

18. Clausell N, Kalil P, Biolo A, Molossi S, Azevedo M. Increased expression of tumor necrosis factor-α in diabetic macrovasculopathy. Cardiovasc Pathol. 1999;8(3):145-51.

19. Moller DE. Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11(6):212-7.

20. Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J. Evidence for control of tumour necrosis factor-alpha (TNF-α) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;115(3):409-14.

21. Bilsborough W, O'Driscoll G, Stanton K, Weerasooriya R, Dembo L, Taylor R, Green D. Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in type II diabetes. Clin Sci (Lond). 2002;103(2):163-9.

22. Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621-5.

23. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10(1):19-29.

24. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112(12):1785-8.

25. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42(1):53-61.

26. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157-65.

27. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care. 2002;25(8):1320-5.

28. Schmidt Ml, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649-52.

29. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155(1):57-64.

30. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, Brook GJ, Levy Y. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med. 2004; 21(1):39-44.

31. Rodríguez-Morán M, Guerrero-Romero F. Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications. 1999;13(4):211-5.

32. King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26(5):1535-9.

33. Guerrero-Romero F, Rodríguez-Morán M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003;29(1):65-71.

34. Barzilay Jl, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50(10):2384-9.

35. King DE, Mainous AG 3rd, Pearson WS. C-reactive protein, diabetes, and attendance at religious services. Diabetes Care. 2002;25(7):1172-6.

36. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, Wagner O, Minar E. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation. 2003;108(19):2323-8.

37. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92(4A):18J-26J.

38. Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999;341(9):667-78.

39. Cummings DM, King DE, Mainous AG 3rd. C-reactive protein, antiinflammatory drugs, and quality of life in diabetes. Ann Pharmacother. 2003;37(11):1593-7.

40. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397-405.

41. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med. 1999;16(3):212-8.

42. Henkel E, Köhler C, Temelkova-Kurktschiev T, Hanefeld M. [Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study]. Dtsch Med Wochenschr. 2002;127(18):953-7.

43. Lechleitner M, Herold M, Dzien-Bischinger C, Hoppichler F, Dzien A. Tumour necrosis factor-alpha plasma levels in elderly patients with type 2 diabetes mellitusobservations over 2 years. Diabet Med. 2002;19(11):949-53.

44. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulindependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1998;18(8):1199-202.

45. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factoralpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248(1):67-76.

46. Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med. 2001;250(5):415-21.

47. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001;42(7):1586-91.

48. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2001;86(8):3805-8.

49. Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998;21(4):487-93.

50. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNFalpha suppression. FASEB J. 2002;16(3):438-40.